Eli Lilly LLY Outside U.S. — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eli Lilly's outside u.s. — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eli Lilly's outside U.S. — revenue?
- Eli Lilly (LLY) reported outside U.S. — revenue of $7.68B in Q1 2026.
- How has Eli Lilly's outside U.S. — revenue changed year-over-year?
- Eli Lilly's outside U.S. — revenue increased by 81.2% year-over-year, from $4.24B to $7.68B.
- What is the long-term trend for Eli Lilly's outside U.S. — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's outside U.S. — revenue has grown at a 17.2% compound annual growth rate (CAGR), from $11.51B to $21.7B.
- What does outside U.S. — revenue mean?
- This metric represents the total net sales generated from pharmaceutical products sold in markets outside of the United States. It reflects the company's global commercial footprint and its ability to navigate diverse regulatory, pricing, and reimbursement environments across international territories. Monitoring this figure helps investors assess the company's geographic diversification and exposure to global healthcare market dynamics.